Overview
VKTX market data
Price History
VKTX price chart · 1M
- O
- 34.19
- H
- 34.29
- L
- 33.16
- C
- 33.93
- Vol
- 116,168.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $34.19
- Previous Close
- $34.38
- Day High
- $34.29
- Day Low
- $33.16
- 52 Week High
- $42.76
- 52 Week Low
- $27.19
- 7 Day Return
- -1.32%
- 30 Day Return
- +0.25%
- 90 Day Return
- +3.70%
- 1 Year Return
- +8.46%
- Daily Notional Volume
- $3.9M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.96 – $43.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.9B · P/B 6.22.
Company News
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?The Motley Fool · Aug 27, 2026, 3:15 PM
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65Benzinga · Aug 11, 2026, 2:50 PM
Viking Therapeutics Declined in July, and why its Long-Term Prospects are UndiminishedThe Motley Fool · Aug 6, 2026, 3:02 PM
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetThe Motley Fool · Jul 30, 2026, 11:15 PM
Viking Therapeutics Stock Moves Lower: What's Going On?Benzinga · Jul 30, 2026, 5:08 PM
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114Benzinga · Jul 30, 2026, 3:56 PM
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) EstimateBenzinga · Jul 29, 2026, 8:07 PM
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Is It Too Late to Buy Eli Lilly?The Motley Fool · Jul 8, 2026, 7:15 PM